Article
21 May 2026
Pennsylvania Is Emerging As A Premier Market For Data Centers—Here’s How To Capture The Opportunity
CONTRIBUTING SINCE MARCH 2011
Buchanan Ingersoll & Rooney PC
With 450 attorneys and government relations professionals across 15 offices, Buchanan Ingersoll & Rooney provides progressive legal, business, regulatory and government relations advice to protect, defend and advance our clients’ businesses. We service a wide range of clients, with deep experience in the finance, energy, healthcare and life sciences industries.
POPULAR TOPICS
Food, Drugs, Healthcare, Life Sciences
Cannabis & Hemp
International Law
Employment and HR
Energy and Natural Resources
Buchanan Ingersoll & Rooney PC are most popular:
- with readers working within the Environment & Waste Management industries
DETAILS
United States
+1 412 562 8800
Union Trust Building
501 Grant Street
Suite 200
Pittsburgh
United States
Contact Firm
COMPANY CONTENT
Article
21 May 2026
SEC Proposes Optional Semiannual Reporting
Article
18 May 2026
New Jersey’s Recent “Protecting Against Forever Chemicals Act” Aims To Curb PFAS Exposure From Certain Consumer Products
Article
17 May 2026
The Evolving Responsibilities Of Pharmacists Amid Rising DEA Investigations: What Pharmacies Need To Know Before Agents Walk Through The Door
Article
14 May 2026
Major Online Learning Management System Falls Victim To Cyberattack: Steps Universities Should Take Now To Limit Risk
Article
12 May 2026
Arcadia Mayor To Plead Guilty To Acting As Chinese Foreign Agent
Article
12 May 2026
USTR Greer Testifies Before House Ways And Means Committee: Tariff Exclusion Process Unlikely
Article
11 May 2026
Tennessee’s FAIR Rx Act Marks A Major Escalation In State PBM Reform
Article
06 May 2026
USTR Provides Opportunity To Request Continuation Of Section 301 Tariffs On China
Article
06 May 2026
Defense Counterintelligence And Security Agency (DCSA) Names New Director
Article
06 May 2026
BIS Seeks Significant Funding Increase For FY 2027 Impacting Export Controls Enforcement And Section 232 Tariffs
Article
06 May 2026
Peptides At The Crossroads: FDA Tightens The Line As Category 2 Pushes Toward Category 1
Article
06 May 2026
What FDA’s Latest Peptide Action Really Means For Compounding Pharmacies
Article
06 May 2026
The Illusion Of PBM Transparency: What Plan Sponsors Must Learn From The OPM OIG Audit Of CVS Caremark
Article
05 May 2026
Shaking Up The Workplace: USDOL's Proposed Joint Employment Rule And Its Impact On Employers
Article
30 Apr 2026
House Plaintiffs Move To Exempt Multimedia Rights NIL Deals From Clearinghouse Review
Article
29 Apr 2026
Navigating The Strait Of Hormuz: U.S. Sanctions And Global Oil Markets
Article
28 Apr 2026
The Critical First 30 Days: A Defense Perspective On Managing Traumatic Accident Claims
Article
28 Apr 2026
Cosmetics Industry Update: What’s New With MoCRA?
Article
10 Apr 2026
Ohio Legislatures Sign PBM Reform Into Law
AWARDS
